Claims for Patent: 8,540,965

Summary for Patent: 8,540,965

Title:	Single wall nanotube constructs and uses therefor
Abstract:	The present invention provides soluble single wall nanotube constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble single wall carbon nanotube via a DNA or other oligomer platform attached to the single wall carbon nanotube. These soluble single wall carbon nanotube constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble single wall carbon nanotube constructs.
Inventor(s):	Scheinberg; David A. (New York, NY), McDevitt; Michael (Bronx, NY), Antczak; Christophe (New York, NY), Chattopadhyay; Debjit (Pennington, NJ), May; Rena (Richmond, VA), Njardarson; Jon (Ithaca, NY), Philips; Mark Reid (New York, NY)
Assignee:	Sloan-Kettering Institute for Cancer Research (New York City, NY)
Application Number:	11/989,672
Patent Claims:	1. A method of treating a pathophysiological state in a subject, comprising: administering a soluble single wall carbon nanotube (SWNT) construct functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereon, wherein the SWNT construct has a structure of SWNT-(DNA.sub.1,2-(cDNA.sub.1-peptide).sub.m-(cDNA.sub.2-M*tetraazacyclod- odecane-1,4,7,10-tetraacetic acid (DOTA)).sub.n).sub.x, such that cDNA.sub.1 is linked to the peptide, cDNA.sub.2 is linked to DOTA and DNA.sub.1,2 is linked to the SWNT; and, wherein cDNA.sub.1 and cDNA.sub.2 independently are non-identical oligomers and DNA.sub.1,2 is an oligomer with a sequence complementary to cDNA.sub.1 and cDNA.sub.2; and, wherein said DNA.sub.1,2 is the sequence shown in SEQ ID NO: 1, said cDNA.sub.1 is the sequence shown in SEQ ID NO: 2, and said cDNA.sub.2 is the sequence shown in SEQ ID NO: 3; and, wherein said peptide is an antibody or a targeting cyclic RGD or an NGR peptide ligand, M* is a radionuclide, x is 1 to 300; and m and n are independently 1 to 300; and wherein, upon targeting cells associated with the pathophysiological state with said targeting moiety, said payload has a therapeutic effect against said cells or elicits a therapeutic effect from said cells thereby treating the pathophysiological state in the subject. 2. The method of claim 1, wherein said antibody is rituximab, trastuzumab, or antinucleolin. 3. The method of claim 1, wherein said radionuclide is actinium-225, astatine-211, indium-111, technetium-99, lutetium-177, gallium-68, holmium-166, bismuth-212, bismuth-213, yttrium-86, yttrium-90, copper-64, copper-67, samarium-117, samarium-153, iodine-123, iodine-124, iodine-125, or iodine-131. 4. The method of claim 1, wherein the peptide is a targeting therapeutic antibody and the radionuclide is a diagnostic radionuclide, the method further comprising: imaging a location of said therapeutic antibody after administering the soluble single wall carbon nanotube (SWNT) construct. 5. The method of claim 4, wherein the therapeutic targeting antibody is rituximab and the diagnostic radionuclide is yttrium-86. 6. The method of claim 1, wherein said cells associated with the pathophysiological state are cancer cells, vascular endothelial cells or activated T cells.

Details for Patent 8,540,965

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2025-07-29
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2025-07-29
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2025-07-29
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2025-07-29
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2025-07-29
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2025-07-29